Datapoint: Pfizer Scores Endometriosis Nod for Myfembree

The FDA last week approved Pfizer’s Myfembree for the treatment of moderate to severe endometriosis pain in pre-menopausal women. The once-daily pill was first approved for the treatment of uterine fibroids in May 2021. For this indication, the drug currently holds covered or better status for 80% of all insured lives, with 44.8% having preferred access to Myfembree.

SOURCE: MMIT Analytics, as of 8/10/22

0 Comments
© 2024 MMIT
Carina Belles

Carina Belles

Carina has been covering public-sector health care since 2018. As a data reporter for Radar on Medicare Advantage, she creates infographics and data stories on issues impacting Medicare, Medicaid and Part D. She also develops AIS Health Daily, a free daily newsletter that showcases AIS’s strong reporting across our four publications and parent company Norstella’s suite of market access and data solutions. Prior to joining the editorial team, she managed Medicare and Medicaid data for the Directory of Health Plans, AIS’s industry-standard health coverage database. She graduated from Ohio University with a B.S. in Journalism.

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 18

Datapoint: Arcutis Scores New Indication for Zoryve

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 17

Datapoint: Blue Shield of California Adds New Weight Loss, Diabetes Programs to Digital Health Platform

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 16

Datapoint: Sanford, Marshfield Clinic to Merge

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today